20-F/A: GH Research PLC Amends Annual Report, Highlights Strong Clinical Data for Depression Therapies Amidst FDA Clinical Hold and Funding Needs

GH Research PLC filed an amendment to its 2024 annual report, confirming robust Phase 2b clinical trial results for its lead depression candidate GH001, while navigating an ongoing FDA clinical hold and outlining future funding requirements.

Summary

• GH Research PLC reported a net loss of $39.0 million for the year ended December 31, 2024, increasing from $35.6 million in 2023, with an accumulated deficit of $106.4 million as of December 31, 2024.
• Cash, cash equivalents, other financial assets, and marketable securities totaled $182.6 million as of December 31, 2024, down from $222.7 million in 2023.
• Net cash used in operating activities increased to $42.3 million in 2024 from $33.3 million in 2023, primarily due to increased clinical development and nonclinical activities.
• The company successfully met the primary endpoint of its Phase 2b trial (GH001-TRD-201) for GH001 in Treatment-Resistant Depression (TRD), showing a significant reduction of -15.2 points in MADRS total score on Day 8 compared to placebo (+0.3 points, difference of -15.5 points, p<0.0001).
• In the open-label extension (OLE) phase of the GH001-TRD-201 trial, as of January 22, 2025, 77.8% of patients were in remission (MADRS <= 10) at the 6-month visit, and 91.7% of Day 8 remitters maintained remission at 6 months.
• The FDA placed a clinical hold on GH001's Investigational New Drug (IND) application in September 2023, requesting additional inhalation toxicology studies and device design verification information; the company completed the requested toxicology studies by January 10, 2025, and plans to submit a complete response to the FDA in mid-2025.
• GH002, an intravenous mebufotenin product candidate, completed a Phase 1 trial in healthy volunteers, demonstrating it was well tolerated with potent, ultra-rapid psychoactive effects and a short duration (5-30 minutes).
• The company estimates a market opportunity of approximately 9 million TRD patients in the United States and Europe.
• GH Research PLC holds over 35 patent families and more than 250 patent applications globally, with expected expiry dates ranging from 2040 to 2049.
• The company remediated previously identified material weaknesses in its internal control over financial reporting as of December 31, 2024.

Sentiment

Score: 7

Explanation: The filing presents a mixed but overall positive outlook. The strong efficacy and safety data from the GH001 Phase 2b trial and its OLE are significant positives, demonstrating potential for a practice-changing treatment in TRD. The recent capital raise also significantly improves liquidity. However, the ongoing FDA clinical hold and the inherent challenges of controlled substance rescheduling represent substantial regulatory hurdles and uncertainties. The company's continued losses and reliance on future funding are expected for a clinical-stage biotech but remain financial risks. The remediation of internal control weaknesses is a positive operational sign.

Positives

• GH001 Phase 2b trial in TRD met its primary endpoint with a statistically significant and clinically meaningful reduction in MADRS score on Day 8.
• High rates of remission (77.8%) and response (81.5%) were observed at the 6-month visit in the open-label extension phase of the GH001-TRD-201 trial, with 91.7% of Day 8 remitters maintaining remission.
• GH001 was well tolerated across all completed Phase 1 and Phase 2a/b trials, with no severe or serious adverse events reported in the double-blind phase of the Phase 2b trial or the OLE phase as of January 22, 2025.
• Completion of requested inhalation toxicology studies for GH001 IND by January 10, 2025, with the non-rodent study showing no respiratory tract histology findings.
• GH002 Phase 1 trial showed the intravenous formulation was well tolerated with potent, ultra-rapid, and short-duration psychoactive effects.
• The company maintains a robust intellectual property portfolio with over 250 patent applications globally, protecting various aspects of mebufotenin use, compositions, manufacturing, and delivery devices.
• Material weaknesses in internal control over financial reporting were remediated as of December 31, 2024.
• Received net cash proceeds of $139.8 million from a public offering of ordinary shares in 2025, significantly bolstering liquidity.

Negatives

• The company incurred significant net losses of $39.0 million in 2024 and has an accumulated deficit of $106.4 million, indicating continued cash burn.
• An FDA clinical hold remains on the GH001 IND, requiring additional device design verification and updates, which could cause considerable delays and expenses.
• The company relies completely on third parties for manufacturing and supply of drug substance, product candidates, and medical devices, including sole-source suppliers for some materials, posing supply chain risks.
• Mebufotenin is currently classified as a Schedule I drug in the United States, requiring rescheduling by the DEA for commercial marketing, a process that is uncertain and could be delayed.
• The company has no marketing and sales organization and no experience in commercializing products, requiring significant future investment and capabilities development.
• The rat inhalation toxicology study for GH001 showed histology findings consistent with previous studies, which contributed to the FDA clinical hold.
• The company believes it was a Passive Foreign Investment Company (PFIC) for 2024 and anticipates being one in 2025 and potentially future years, which could subject U.S. investors to significant adverse tax consequences.
• The trading market for the company's ordinary shares is relatively illiquid, potentially limiting investors' ability to sell shares.

Risks

• The company is a clinical-stage biopharmaceutical company with significant accumulated losses and expects to incur substantial losses for the foreseeable future.
• Substantial additional funding will be needed, which may not be available on acceptable terms or at all, potentially forcing delays or elimination of development programs.
• Preliminary, top-line, or interim clinical trial data may change upon full analysis and verification, potentially harming business and prospects.
• Resolution of the FDA clinical hold on GH001 IND may take considerable time and expense, with no assurance of removal, materially affecting clinical development.
• Drug and drug-device combination product development is highly uncertain and involves substantial risk.
• GH001 and GH002 are novel mebufotenin therapies, making development time and cost difficult to predict, and no such therapies are yet approved in the US or EU.
• Developing the proprietary aerosol delivery device for GH001 is costly and uncertain; failure or delay could materially adversely affect the business.
• Clinical development is lengthy, complex, and expensive, with uncertain outcomes; early trial results may not predict later success, and European trial results may not satisfy FDA/EMA requirements.
• Product candidates may cause undesirable side effects, potentially delaying or preventing regulatory approval or limiting commercial potential.
• Controlled substance laws and regulations (e.g., Schedule I classification in US) pose compliance burdens and risks, including potential delays in approval and rescheduling.
• Commercial success depends on significant market acceptance by physicians, patients, and third-party payors.
• Reliance on third parties for nonclinical studies and clinical trials; unsatisfactory performance could cause delays or harm.
• Development and manufacture of active pharmaceutical ingredients, product candidates, and medical devices are complex, with potential difficulties in production and reliance on sole-source third-party suppliers.
• Dependence on executive officers and principal consultants; loss of their services would materially harm the business.
• Risk of future material weaknesses in internal control over financial reporting despite remediation efforts.
• Exposure to economic, political, regulatory, and other risks associated with international operations, including supply chain disruptions from geopolitical tensions (e.g., China-Taiwan).
• Cyber-attacks or failures in IT systems could result in information theft, data corruption, and business disruption.
• Market price volatility of ordinary shares due to various factors, including clinical trial results, regulatory approvals, and competitor actions.
• Future sales of securities by existing shareholders could depress the market price.
• Executive officers, directors, and significant shareholders may exercise control over the company, potentially with differing interests from other shareholders.
• The trading market for ordinary shares is relatively illiquid.
• The company has never paid cash dividends and does not anticipate doing so, with legal limitations on dividend payments.
• Dividends paid may be subject to Irish dividend withholding tax.
• Ordinary shares received by gift or inheritance could be subject to Irish capital acquisitions tax.
• Lack of continued research or inaccurate/unfavorable research by securities analysts could cause share price decline.
• Shareholders could be diluted due to disapplication of statutory preemption rights.
• Increased risk of securities class action litigation.
• Irish law differs from U.S. law and may afford less protection to shareholders; U.S. civil liabilities may not be enforceable in Ireland.
• Loss of foreign private issuer status could result in significant additional cost and expense.
• Ongoing healthcare legislative and regulatory reform measures may adversely affect business and results of operations.
• Potential for multi-agency enforcement post-rescheduling of mebufotenin, including state agencies, could threaten or materially adversely affect the business.
• Public controversy and negative perception regarding mebufotenin and psychedelics generally could negatively influence therapy success.
• Inability to obtain or maintain necessary rights to product candidates or medical devices through acquisitions and in-licenses.
• Changes in patent laws or jurisprudence could diminish patent value or prevent adequate protection.
• Failure to obtain or maintain trade secret protection could adversely affect competitive position.
• Inability to protect intellectual property rights throughout the world, facing difficulties in certain jurisdictions.
• Non-compliance with environmental, health, and safety laws and regulations could lead to fines or penalties.

Future Outlook

The company expects to continue incurring significant losses and increasing expenses as it advances clinical development of GH001 and GH002, expands manufacturing capabilities, pursues additional product candidates, seeks regulatory approvals, and builds commercial infrastructure. It anticipates needing substantial additional funding beyond its current cash runway, which is estimated to be sufficient for at least the next 12 months. The company plans to submit a complete response to the FDA regarding the GH001 clinical hold in mid-2025 and aims to maximize ultra-rapid and durable remissions with single-visit initial treatment and infrequent re-treatment for its mebufotenin therapies.

Management Comments

• Management believes that existing cash, cash equivalents, other financial assets, and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements for at least the next 12 months.
• Management has concluded that actions taken to design and maintain internal control over financial reporting, as well as testing results, remediated previously identified material weaknesses as of December 31, 2024.
• Management regularly consults with professional tax advisors when establishing tax filing positions and believes that the tax filing positions taken are in accordance with tax regulations.

Industry Context

GH Research operates in the highly competitive biopharmaceutical industry, specifically targeting psychiatric and neurological disorders, with an initial focus on Treatment-Resistant Depression (TRD). The market for TRD is substantial, with an estimated 9 million patients in the US and Europe, and a significant unmet medical need due to limitations of existing therapies like SSRIs, SNRIs, atypical antidepressants, and even newer treatments like esketamine and olanzapine/fluoxetine combinations. The company's novel mebufotenin therapies aim to provide ultra-rapid and durable remissions, differentiating themselves from current options which often have slow onset or significant side effects. The industry faces increasing scrutiny over drug pricing and reimbursement, as well as evolving regulatory landscapes for novel drug-device combination products and controlled substances. Competitors include established pharmaceutical companies and other biotech firms developing psychedelic-based therapies, such as ATAI Life Sciences, Beckley Psytech, COMPASS Pathways, Cybin, and Mindmed, with COMPASS Pathways having an advanced Phase 3 program for psilocybin in TRD.

Comparison to Industry Standards

• The company's GH001 Phase 2b trial results showing a -15.5 point reduction in MADRS score compared to placebo on Day 8 indicate a rapid and significant antidepressant effect, which is a key differentiator in the TRD market where existing treatments often have a slow onset (average 5-7 weeks to remission in STAR*D study).
• The 77.8% remission rate at 6 months in the GH001 OLE phase is notably high compared to the STAR*D study, which showed remission rates of 37% for first-line and significantly lower for subsequent treatment steps (14% for third antidepressant treatment, less than 5% staying in remission for one year after two failed therapies).
• The company's focus on a 'single visit initial treatment, without additional mandated visits for psychotherapeutic intervention' and 'convenient and infrequent re-treatment' aims to address the high burden and frequent administration requirements of some approved TRD therapies, such as SPRAVATO (esketamine) which requires frequent in-clinic administration (e.g., twice-weekly for 4 weeks, then weekly/bi-weekly, estimated 40 visits/year).
• The challenge of mebufotenin's Schedule I classification in the US is a significant hurdle, as no mebufotenin therapies have received FDA approval or EU marketing authorization, unlike esketamine (SPRAVATO) which is approved for TRD and is a Schedule III controlled substance, indicating a more established regulatory pathway for its class.

Management Changes

Corporate Governance

Legal Proceedings

• Not a party to any material litigation and did not have material contingency reserves established for any liabilities as of December 31, 2024.

Related Party Transactions

• The company's Constitution requires indemnification of directors and executive officers, employees, and other officials to the fullest extent permitted by Irish law.
• A related person transaction policy has been adopted, requiring approval or ratification by the Board of Directors or a designated committee for any related person transactions.
• Share options were granted to key management (executive officers and directors) in 2023 and 2024, with varying vesting schedules and exercise prices.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings and adverse U.S. federal income tax consequences if the company remains a PFIC.
• Shareholders' ability to sell shares may be limited due to the relatively illiquid trading market.
• Employees benefit from share option plans designed to attract, retain, and motivate, but the company faces competition for qualified personnel.
• Patients with TRD, Bipolar II Disorder, and Postpartum Depression could benefit from novel, rapidly acting, and durable mebufotenin therapies if approved.
• Suppliers and contractors are critical to the company's operations, with reliance on sole-source suppliers posing risks to development and commercialization timelines.
• Regulatory bodies (FDA, EMA, DEA) are key stakeholders, as their approvals and scheduling decisions are critical for product development and commercialization.

Next Steps

• Submit a complete response to the FDA regarding the GH001 clinical hold in mid-2025.
• Continue the 6-month open-label extension phase of the GH001-TRD-201 trial, with last patient visit completion on track for Q1 2025.
• Advance the clinical development of GH001 for TRD and evaluate additional opportunities in psychiatric and neurological disorders.
• Advance GH002, the intravenous mebufotenin product candidate, through clinical development.
• Investigate additional delivery systems and routes of administration for mebufotenin.
• Expand the intellectual property portfolio around mebufotenin.
• Maximize the value of the product portfolio by building internal commercialization infrastructure and entering selective partnerships.
• Seek regulatory approvals for product candidates and medical devices required for delivery.
• Hire and retain additional personnel, including clinical, quality control, scientific, commercial, sales, marketing, and administrative staff.

Key Dates

Recommendation

While the Phase 2b clinical data for GH001 in TRD is highly promising, demonstrating significant efficacy and durability, the company faces substantial regulatory hurdles, particularly the ongoing FDA clinical hold and the complex process of rescheduling mebufotenin as a controlled substance. These factors introduce significant uncertainty regarding the timeline and ultimate success of commercialization. The company's continued operating losses and reliance on future capital raises, despite a recent offering, also present financial risks. A 'Hold' recommendation acknowledges the strong clinical potential while emphasizing the material regulatory and financial uncertainties that need to be resolved before a more definitive investment stance can be taken.

Keywords

Mebufotenin, Treatment-Resistant Depression, TRD, GH001, GH002, Clinical Trial, Phase 2b, FDA Clinical Hold, Biopharmaceutical, Psychiatric Disorders, Neurological Disorders, Drug-Device Combination, Controlled Substances Act, SEC Filing, Annual Report, IFRS, Nasdaq